Nurses’ perceptions, experiences, and practices regarding human papillomavirus vaccination in a large, rural U.S. state
Author:
Thaker Juthika1, Albers Alexandria N.1, Newcomer Sophia R.1
Abstract
AbstractPurpose:Nationally, much of the focus on improving human papillomavirus (HPV) vaccine uptake has focused on effective strategies physicians can use to promote vaccination. However, in large, rural states like Montana, nurses and medical assistants play critical roles in immunization services delivery, and their viewpoints are imperative in designing strategies to increase vaccination rates.Methods:We designed, pilot tested, and disseminated an online survey instrument to nurses and medical assistants working in clinics participating in the Vaccines for Children program in Montana. Survey questions focused on clinic vaccination practices, respondents’ perceptions of the HPV vaccine, perceived barriers to vaccine uptake, and general opinions on potential strategies to improve HPV vaccination rates.Results:We analyzed data from 227 respondents. Overall, 90% of nurses strongly agreed or agreed that the HPV vaccine is important and had confidence in the vaccine’s safety. More nurses reported experiencing greater parental vaccine refusal or delay for male patients regardless of age. About 53.7% of nurses indicated that their clinics had reminder/recall systems to encourage parents to bring their children for vaccination. Nurses identified misinformation from social media, infrequent wellness visits, and vaccine safety concerns as barriers to HPV vaccine uptake.Conclusion:Study findings identified several promising initiatives to accelerate vaccination in rural states like Montana, including promoting widespread adoption of reminder/recall systems, training nurses in evidence-based techniques to provide strong vaccine recommendations, and leveraging social media to disseminate consistent messages about the HPV vaccine recommendations for both sexes and its role in cancer prevention.
Publisher
Research Square Platform LLC
Reference59 articles.
1. 1. Centers for Disease Control and Prevention. (2021, July 23). HPV infection. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/hpv/parents/about-hpv.html 2. 2. Centers for Disease Control and Prevention. (2022, March 9). HPV vaccine-preventable diseases surveillance manual. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html 3. 3. Newcomer, S. R., Freeman, R. E., Albers, A. N., Murgel, S., Thaker, J., Rechlin, A., & Wehner, B. K. (2022). Missed opportunities for human papillomavirus vaccine series initiation in a large, rural U.S. state. Human Vaccines & Immunotherapeutics, 18(1), 2016304. https://doi.org/10.1080/21645515.2021.2016304 4. 4. Hernández-Ávila, M., Torres-Ibarra, L., Stanley, M., Salmerón, J., Cruz-Valdez, A., Muñoz, N., et al. (2015). Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Informa UK Limited. doi:10.1080/21645515.2015.1058458 5. 5. Yih, W. K., Greene, S. K., Zichittella, L., Kulldorff, M., Baker, M. A., de Jong, Jill L. O, et al. (2015). Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females. Vaccine, 34(1), 172–178. doi:10.1016/j.vaccine.2015.09.087
|
|